drugset / Trial / NCT03330795
Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant
Phase 1/2
Completed
5 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
PPD Development, LP · collabUniversity of Pittsburgh · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched CD3+/CD19+ depleted bone marrow transplant (BMT) is safe and effective for individuals aged 10 through 45 years with the diagnosis of primary immunodeficiency (PID) and end-stage lung disease. The enrollment goal: 8 participants who receive both BOLT and BMT.
Timeline
- Start
- 2017-12-01
- Primary completion
- 2024-03-01
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD3/CD19 neg allogeneic BMT | Cell therapy | — | — |